Enhanced in vivo adenovirus-mediated gene transfer to rat hepatocarcinomas by selective administration into the hepatic artery

被引:46
作者
Gerolami, R
Cardoso, J
Bralet, MP
Cuenod, CA
Clement, O
Tran, PL
Brechot, C
机构
[1] Hop Necker Enfants Malad, INSERM, U370, F-75730 Paris 15, France
[2] Hop Cochin, INSERM, CRI 94 05, Lab Rech Chirurg, F-75674 Paris, France
[3] Hop Necker Enfants Malad, INSERM, U66, Lab Rech Imagerie, Paris, France
[4] Hop Necker Enfants Malad, INSERM, U25, Paris, France
关键词
primary liver cancer; gene transfer; recombinant adenoviruses; computerized tomography; vascularization;
D O I
10.1038/sj.gt.3300664
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Adenovirus-mediated gene therapy of experimental hepatocarcinoma is hindered by low transduction efficacy in vivo. We evaluated the extent of gene expression following various routes of administration of recombinant adenovirus AdCMVlacZ in diethylnitrosamine-induced rat hepatocarcinoma. We first characterized the vascularization of diethylnitrosamine-induced hepatocarcinomas using a computerized tomography scanner approach. The efficacy of gene transfer was then evaluated by three routes of administration: intraportal, selective injection through the hepatic artery and direct injection into the tumor. Diethylnitrosamine-induced hepatocarcinomas had predominantly an arterial blood supply, 67% of the total liver blood supply. Compared with intraportal administration, arterial injection improved gene transfer into tumors whereas that to the non-tumor areas was diminished. In addition, this route of injection allowed the efficient transduction of dysplastic nodules. Diethylnitrosamine-induced hepatocarcinoma in rats is a relevant model for the study of human hepatocarcinoma due to its vascularization. Arterial infusion improved the ratio of transduced tumorous to nontumorous cells and allowed targeting of gene transfer to dysplastic nodules. This will be useful in the design of gene therapy for hepatocarcinoma.
引用
收藏
页码:896 / 904
页数:9
相关论文
共 35 条
[1]   RISK-FACTORS FOR INTRAHEPATIC RECURRENCE IN HUMAN SMALL HEPATOCELLULAR-CARCINOMA [J].
ADACHI, E ;
MAEDA, T ;
MATSUMATA, T ;
SHIRABE, K ;
KINUKAWA, N ;
SUGIMACHI, K ;
TSUNEYOSHI, M .
GASTROENTEROLOGY, 1995, 108 (03) :768-775
[2]   Hepatoma cell-specific expression of a retrovirally transferred gene is achieved by alpha-fetoprotein but not insulinlike growth factor II regulatory sequences [J].
Arbuthnot, P ;
Bralet, MP ;
Thomassin, H ;
Danan, JL ;
Brechot, C ;
Ferry, N .
HEPATOLOGY, 1995, 22 (06) :1788-1796
[3]   In vitro and in vivo hepatoma cell-specific expression of a gene transferred with an adenoviral vector [J].
Arbuthnot, PB ;
Bralet, MP ;
LeJossic, C ;
Dedieu, JF ;
Perricaudet, M ;
Brechot, C ;
Ferry, N .
HUMAN GENE THERAPY, 1996, 7 (13) :1503-1514
[4]   Adenoviral delivery of recombinant DNA into transgenic mice bearing hepatocellular carcinomas [J].
Bao, JJ ;
Zhang, WW ;
Kuo, MT .
HUMAN GENE THERAPY, 1996, 7 (03) :355-365
[5]   INTRAHEPATIC RECURRENCE AFTER RESECTION OF HEPATOCELLULAR-CARCINOMA COMPLICATING CIRRHOSIS [J].
BELGHITI, J ;
PANIS, Y ;
FARGES, O ;
BENHAMOU, JP ;
FEKETE, F .
ANNALS OF SURGERY, 1991, 214 (02) :114-117
[6]   IN-VITRO EVIDENCE THAT METABOLIC COOPERATION IS RESPONSIBLE FOR THE BYSTANDER EFFECT OBSERVED WITH HSV TK RETROVIRAL GENE-THERAPY [J].
BI, WL ;
PARYSEK, LM ;
WARNICK, R ;
STAMBROOK, PJ .
HUMAN GENE THERAPY, 1993, 4 (06) :725-731
[7]  
BIOULACSAGE P, 1988, SINUSOIDS HUMAN LIVE, P223
[8]   LIVER RESECTION VERSUS TRANSPLANTATION FOR HEPATOCELLULAR-CARCINOMA IN CIRRHOTIC-PATIENTS [J].
BISMUTH, H ;
CHICHE, L ;
ADAM, R ;
CASTAING, D ;
DIAMOND, T ;
DENNISON, A .
ANNALS OF SURGERY, 1993, 218 (02) :145-151
[9]   LIVER PERFUSION STUDIED WITH ULTRAFAST CT [J].
BLOMLEY, MJK ;
COULDEN, R ;
DAWSON, P ;
KORMANO, M ;
DONLAN, P ;
BUFKIN, C ;
LIPTON, MJ .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 1995, 19 (03) :424-433
[10]  
Bookstein R, 1996, SEMIN ONCOL, V23, P66